ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 246 entries already.
In addition to the uncertainty triggered by the US government with serious changes at the FDA and other healthcare institutions and an unclear stance of the US Secretary of Health and Human Services on various areas of innovation, the growing demand for health care services gives a positive momentum that can provide stability.
In the life sciences industry, Quality Management (QM) has long been synonymous with compliance: checking boxes to meet regulatory demands. But that definition no longer holds up. Today, QM must do much more than ensure compliance; it needs to enable speed, scalability, and sustained innovation across complex, global operations. To do that, prominent gaps need to be filled.
It all began with a view from the window of the 15th floor of Bayer’s site in Berlin, reminiscent of Boston before it became one of the most important biotech hotspots in the world. This inspired the vision of developing the Bayer Campus into “Boston an der Spree” – a vibrant healthcare campus that fosters collaboration and innovation.
In life sciences, breakthroughs are reshaping healthcare faster than ever. But true leadership means going beyond the lab – understanding the complex ecosystem where science, policy, and business collide. For those struggling to navigate this complexity, WU Vienna’s Executive MBA offers the insights and connections needed to stay ahead in an unpredictable industry.
As the global race for biosolutions intensifies, Europe is at a critical crossroads, and I am deeply concerned about the future of our continent’s biotech industry. While countries like China and the United States rapidly advance their biotech industries, Europe’s slow and not up-to-date regulatory system poses a significant risk to maintaining our leadership.
MC2 Therapeutics A/S, a Hørsholm-based pharmaceutical company focused on topical therapies in inflammatory skin conditions, announced the appointment of Trine Ahlgreen as Chief Executive Officer at the end of May.
Italian Sibylla Biotech has appointed a new Chairman of the Board of Directors: Dieter Weinand, former President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG.
Dr Regina Hodits joined Angelini Ventures, the VC arm of Angelini Industries, in April as the new Managing Director. She will be based in Germany and lead the company’s international biotech investment strategy with focus Biotech AI and therapeutics.
NovoArc GmbH, an Austrian biotech startup and BIOTECH AUSTRIA member, develops lipid-based formulations to enable the oral delivery of drugs that currently require injection. Its innovative approach paves the way for more convenient and effective treatments.
Biotechnology provides the necessary toolbox, ranging from energy-saving biocatalysts for the chemical industry to climate-friendly production of animal feed and food proteins for more resilience, microbial recovery of rare critical materials, to the production of pharmaceutically active ingredients.